Kodiak Sciences Inc. Kodiak Sciences Inc.

Kodiak Sciences Inc.

KOD

Rang in Aktien #3122
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical... Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
Aktienkurs
$93.93
Marktkapitalisierung
$5.90B
Veränderung (1 Tag)
2.82%
Veränderung (1 Jahr)
430.65%
Land
US
Handel Kodiak Sciences Inc. (KOD)

Kategorie

Healthcare
P/S-Verhältnis für Kodiak Sciences Inc. (KOD)
P/S-Verhältnis zum October 2026 TTM: 0.00
Laut den neuesten Finanzberichten und dem Aktienkurs von Kodiak Sciences Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0.00. Am Ende des Jahres 2023 lag das P/S-Verhältnis bei 0.00.
P/S-Verlauf für Kodiak Sciences Inc. von 2016 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
10.02 -
US
40.55 -
US
3.96 -
AU
- -
CH
10.15 -
NL